

CLAIMS

- 1.- An ophthalmic pharmaceutical composition comprising:
 - a peptide wherein the peptide is a pharmaceutically acceptable salt of the sequence SEQ ID NO: 2, particularly an acetate salt of the sequence SEQ ID NO: 2; or, alternatively, the peptide is the sequence SEQ ID NO: 2; and
 - one or more pharmaceutically acceptable excipients or carriers;wherein the pH value of the composition is between 4.0 and 4.8 and the osmolality ranges between 0.5 and 200 mOsm/kg.
- 2.- The ophthalmic pharmaceutical composition according to claim 1, wherein the pH value is between 4.1 and 4.8.
- 3.- The ophthalmic pharmaceutical composition according to claim 1 or claim 2, wherein the osmolality ranges from 1 to 150 mOsm/kg.
- 4.- The ophthalmic pharmaceutical composition according to any one of claims 1-3, wherein at least one of the one or more pharmaceutically acceptable excipients or carriers is selected from the group consisting of a stabilizing agent, a viscosifying agent, a buffering agent and mixtures thereof.
- 5.- The ophthalmic pharmaceutical composition according to claim 4, wherein the stabilizing agent is aspartic acid or glutamic acid.
- 6.- The ophthalmic pharmaceutical composition according to any one of claims 1-5, further comprising an effective amount of a preservative.
- 7.- The ophthalmic pharmaceutical composition according to claim 6, wherein the preservative is selected from edetate sodium, benzalkonium chloride, centrimonium chloride, sodium perborate, stabilized oxychloro complex, sorbic acid, thimerosal, polyquarternium-1, polyhexamethylene biguanide, chlorobutanol, phenylethyl alcohol, methylparaben, propylparaben, a combination of boric acid, sorbic acid, and propylene glycol; and mixtures thereof, preferably the preservative is benzalkonium chloride.
8. A lyophilizate comprising the peptide as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable amount of a stabilizing agent and/or buffering agent, wherein said lyophilizate is suitable for preparing the ophthalmic pharmaceutical composition according to any one of claims 1- 7 by reconstitution.

9. A process for preparing the ophthalmic pharmaceutical composition according to any one of claims 1 to 7, which comprises the step of reconstituting the lyophilizate as defined in claim 8 with an aqueous vehicle composition comprising one or more pharmaceutically acceptable carriers or excipients, particularly an aqueous vehicle composition comprising at least one viscosifying agent and optionally at least one preservative.
10. An ophthalmic pharmaceutical composition according to any one of claims 1 to 7 for use in the topical eye treatment and/or prevention of a retinal neurodegenerative disease.
11. A kit comprising the lyophilizate as defined in claim 8 and a physiologically acceptable vehicle composition comprising one or more pharmaceutically acceptable excipients or carriers, for reconstituting the lyophilizate.
12. A kit comprising the ophthalmic pharmaceutical composition as defined in any one of claims 1-7, a container for holding the pharmaceutical composition and a drop dispenser adapted for administering a volume of the composition.